Cannabinoids and dementia: A review of clinical and preclinical data

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2689-2708

  Walther, Sebastian ^a   Halpern, Michael ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Alzheimer's disease; Cannabinoids; Huntington's disease; Parkinson's disease; Vascular dementia

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; ARVANIL; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; LEVODOPA; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N METHYL DEXTRO ASPARTIC ACID; NABILONE; QUINPIROLE; RIMONABANT; TETRAHYDROCANNABINOLIC ACID;

ABSENCE OF SIDE EFFECTS; AKINESIA; ALZHEIMER DISEASE; BRAIN ISCHEMIA; CLINICAL STUDY; CLINICAL TRIAL; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; EVENING DOSAGE; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; REVIEW; SEIZURE; SUICIDAL IDEATION;

EID: 77957276480     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082689     Document Type: Review

References (131)

1. Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P.R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: A delphi consensus study. Lancet 2005, 366, 2112-2117.
2. Blennow, K.; de Leon, M.J.; Zetterberg, H. Alzheimer's disease. Lancet 2006, 368, 387-403.
3. Aarsland, D.; Andersen, K.; Larsen, J.P.; Lolk, A.; Nielsen, H.; Kragh-Sorensen, P. Risk of dementia in parkinson's disease: A community-based, prospective study. Neurology 2001, 56, 730-736.
4. Leys, D.; Henon, H.; Mackowiak-Cordoliani, M.A.; Pasquier, F. Poststroke dementia. Lancet Neurol. 2005, 4, 752-759.
5. Kumar, P.; Kalonia, H.; Kumar, A. Huntington's disease: Pathogenesis to animal models. Pharmacol. Rep. 2010, 62, 1-14.
6. Citron, M. Alzheimer's disease: Strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9, 387-398.
7. Lees, A.J.; Hardy, J.; Revesz, T. Parkinson's disease. Lancet 2009, 373, 2055-2066.
8. Walker, F.O. Huntington's disease. Lancet 2007, 369, 218-228.
9. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462.
10. Gaoni, Y.; Mechoulam, R. Isolation, structure, and partial synthesis of active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646-1647.
11. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cdna. Nature 1990, 346, 561-564.
12. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
13. Breivogel, C.S.; Childers, S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 1998, 5, 417-431.
14. Campbell, V.A.; Gowran, A. Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 2007, 152, 655-662.
15. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International union of pharmacology. Xxvii. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202.
16. Howlett, A.C.; Breivogel, C.S.; Childers, S.R.; Deadwyler, S.A.; Hampson, R.E.; Porrino, L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47 (Suppl. 1), 345-358.
17. Pertwee, R.G. The diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153, 199-215.
18. Wegener, N.; Koch, M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009, 42 (Suppl. 1), S79-S86.
19. Wilson, R.I.; Nicoll, R.A. Endocannabinoid signaling in the brain. Science 2002, 296, 678-682.
20. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372, 686-691.
21. Glass, M.; Dragunow, M.; Faull, R.L. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77, 299-318.
22. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 1990, 87, 1932-1936.
23. Katona, I.; Rancz, E.A.; Acsady, L.; Ledent, C.; Mackie, K.; Hajos, N.; Freund, T.F. Distribution of cb1 cannabinoid receptors in the amygdala and their role in the control of gabaergic transmission. J. Neurosci. 2001, 21, 9506-9518.
24. Katona, I.; Sperlagh, B.; Sik, A.; Kafalvi, A.; Vizi, E.S.; Mackie, K.; Freund, T.F. Presynaptically located cb1 cannabinoid receptors regulate gaba release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19, 4544-4558.
25. Basavarajappa, B.S.; Nixon, R.A.; Arancio, O. Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration. Mini Rev. Med. Chem. 2009, 9, 448-462.
26. Benito, C.; Nunez, E.; Pazos, M.R.; Tolon, R.M.; Romero, J. The endocannabinoid system and alzheimer's disease. Mol. Neurobiol. 2007, 36, 75-81.
27. Campillo, N.E.; Paez, J.A. Cannabinoid system in neurodegeneration: New perspectives in alzheimer's disease. Mini Rev. Med. Chem. 2009, 9, 539-559.
28. Fernandez-Ruiz, J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156, 1029-1040.
29. Hillard, C.J. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr. Pharm. Des. 2008, 14, 2347-2361.
30. Lastres-Becker, I.; De Miguel, R.; Fernandez-Ruiz, J.J. The endocannabinoid system and huntington's disease. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 335-347.
31. Walsh, D.M.; Selkoe, D.J. Deciphering the molecular basis of memory failure in alzheimer's disease. Neuron 2004, 44, 181-193.
32. Zhu, X.; Raina, A.K.; Perry, G.; Smith, M.A. Alzheimer's disease: The two-hit hypothesis. Lancet Neurol. 2004, 3, 219-226.
33. Iuvone, T.; Esposito, G.; De Filippis, D.; Scuderi, C.; Steardo, L. Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neurosci. Ther. 2009, 15, 65-75.
34. Marchalant, Y.; Cerbai, F.; Brothers, H.M.; Wenk, G.L. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol. Aging 2008, 29, 1894-1901.
35. Marchalant, Y.; Rosi, S.; Wenk, G.L. Anti-inflammatory property of the cannabinoid agonist win-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 2007, 144, 1516-1522.
36. Katona, I.; Urban, G.M.; Wallace, M.; Ledent, C.; Jung, K.M.; Piomelli, D.; Mackie, K.; Freund, T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 2006, 26, 5628-5637.
37. Bal-Price, A.; Brown, G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 2001, 21, 6480-6491.
38. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23, 1398-1405.
39. Westlake, T.M.; Howlett, A.C.; Bonner, T.I.; Matsuda, L.A.; Herkenham, M. Cannabinoid receptor binding and messenger rna expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and alzheimer's brains. Neuroscience 1994, 63, 637-652.
40. Benito, C.; Nunez, E.; Tolon, R.M.; Carrier, E.J.; Rabano, A.; Hillard, C.J.; Romero, J. Cannabinoid cb2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains. J. Neurosci. 2003, 23, 11136-11141.
41. Ramirez, B.G.; Blazquez, C.; del Pulgar, T. G.; Guzman, M.; de Ceballos, M.L. Prevention of alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25, 1904-1913.
42. Shen, M.; Piser, T.M.; Seybold, V.S.; Thayer, S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 1996, 16, 4322-4334.
43. Shen, M.; Thayer, S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 1998, 54, 459-462.
44. Marsicano, G.; Goodenough, S.; Monory, K.; Hermann, H.; Eder, M.; Cannich, A.; Azad, S.C.; Cascio, M.G.; Gutierrez, S.O.; van der Stelt, M.; Lopez-Rodriguez, M.L.; Casanova, E.; Schutz, G.; Zieglgansberger, W.; Di Marzo, V.; Behl, C.; Lutz, B. Cb1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302, 84-88.
45. Hansen, H.H.; Schmid, P.C.; Bittigau, P.; Lastres-Becker, I.; Berrendero, F.; Manzanares, J.; Ikonomidou, C.; Schmid, H.H.; Fernandez-Ruiz, J.J.; Hansen, H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 2001, 78, 1415-1427.
46. van der Stelt, M.; Veldhuis, W.B.; Bar, P.R.; Veldink, G.A.; Vliegenthart, J.F.; Nicolay, K. Neuroprotection by delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 2001, 21, 6475-6479.
47. van der Stelt, M.; Veldhuis, W.B.; van Haaften, G.W.; Fezza, F.; Bisogno, T.; Bar, P.R.; Veldink, G.A.; Vliegenthart, J.F.; Di Marzo, V.; Nicolay, K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 2001, 21, 8765-8771.
48. Milton, N.G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 2002, 332, 127-130.
49. Esposito, G.; De Filippis, D.; Steardo, L.; Scuderi, C.; Savani, C.; Cuomo, V.; Iuvone, T. Cb1 receptor selective activation inhibits beta-amyloid-induced inos protein expression in c6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci. Lett. 2006, 404, 342-346.
50. Khaspekov, L.G.; Brenz Verca, M.S.; Frumkina, L.E.; Hermann, H.; Marsicano, G.; Lutz, B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 2004, 19, 1691-1698.
51. Molina-Holgado, F.; Pinteaux, E.; Moore, J.D.; Molina-Holgado, E.; Guaza, C.; Gibson, R.M.; Rothwell, N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 2003, 23, 6470-6474.
52. Grunblatt, E.; Zander, N.; Bartl, J.; Jie, L.; Monoranu, C.M.; Arzberger, T.; Ravid, R.; Roggendorf, W.; Gerlach, M.; Riederer, P. Comparison analysis of gene expression patterns between sporadic alzheimer's and parkinson's disease. J. Alzheimers Dis. 2007, 12, 291-311.
53. Ehrhart, J.; Obregon, D.; Mori, T.; Hou, H.; Sun, N.; Bai, Y.; Klein, T.; Fernandez, F.; Tan, J.; Shytle, R.D. Stimulation of cannabinoid receptor 2 (cb2) suppresses microglial activation. J. Neuroinflammation 2005, 2, 29.
54. Maresz, K.; Carrier, E.J.; Ponomarev, E.D.; Hillard, C.J.; Dittel, B.N. Modulation of the cannabinoid cb2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 2005, 95, 437-445.
55. Tolon, R.M.; Nunez, E.; Pazos, M.R.; Benito, C.; Castillo, A.I.; Martinez-Orgado, J.A.; Romero, J. The activation of cannabinoid cb2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009, 1283, 148-154.
56. Eubanks, L.M.; Rogers, C.J.; Beuscher, A.E.t.; Koob, G.F.; Olson, A.J.; Dickerson, T.J.; Janda, K.D. A molecular link between the active component of marijuana and alzheimer's disease pathology. Mol. Pharm. 2006, 3, 773-777.
57. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaria, R.; Di Rosa, M.; Izzo, A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on beta-amyloidinduced toxicity in pc12 cells. J. Neurochem. 2004, 89, 134-141.
58. Esposito, G.; De Filippis, D.; Carnuccio, R.; Izzo, A.A.; Iuvone, T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through wnt/betacatenin pathway rescue in pc12 cells. J. Mol. Med. 2006, 84, 253-258.
59. Esposito, G.; De Filippis, D.; Maiuri, M.C.; De Stefano, D.; Carnuccio, R.; Iuvone, T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated pc12 neurons through p38 map kinase and nf-kappab involvement. Neurosci. Lett. 2006, 399, 91-95.
60. Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr.; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing il-1beta and inos expression. Br. J. Pharmacol. 2007, 151, 1272-1279.
61. Hayakawa, K.; Mishima, K.; Abe, K.; Hasebe, N.; Takamatsu, F.; Yasuda, H.; Ikeda, T.; Inui, K.; Egashira, N.; Iwasaki, K.; Fujiwara, M. Cannabidiol prevents infarction via the non-cb1 cannabinoid receptor mechanism. Neuroreport 2004, 15, 2381-2385.
62. Leker, R.R.; Gai, N.; Mechoulam, R.; Ovadia, H. Drug-induced hypothermia reduces ischemic damage: Effects of the cannabinoid hu-210. Stroke 2003, 34, 2000-2006.
63. Louw, D.F.; Yang, F.W.; Sutherland, G.R. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 2000, 857, 183-187.
64. Mauler, F.; Hinz, V.; Augstein, K.H.; Fassbender, M.; Horvath, E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist bay 38-7271. Brain Res. 2003, 989, 99-111.
65. Nagayama, T.; Sinor, A.D.; Simon, R.P.; Chen, J.; Graham, S.H.; Jin, K.; Greenberg, D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 1999, 19, 2987-2995.
66. Parmentier-Batteur, S.; Jin, K.; Mao, X.O.; Xie, L.; Greenberg, D.A. Increased severity of stroke in cb1 cannabinoid receptor knock-out mice. J. Neurosci. 2002, 22, 9771-9775.
67. Zani, A.; Braida, D.; Capurro, V.; Sala, M. Delta9-tetrahydrocannabinol (thc) and am 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br. J. Pharmacol. 2007, 152, 1301-1311.
68. Pellegrini-Giampietro, D.E.; Mannaioni, G.; Bagetta, G. Post-ischemic brain damage: The endocannabinoid system in the mechanisms of neuronal death. FEBS J. 2009, 276, 2-12.
69. Cernak, I.; Vink, R.; Natale, J.; Stoica, B.; Lea, P.M.t.; Movsesyan, V.; Ahmed, F.; Knoblach, S.M.; Fricke, S.T.; Faden, A.I. The Dark side Of endocannabinoids: A neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. 2004, 24, 564-578.
70. Savva, G.M.; Stephan, B.C. Epidemiological studies of the effect of stroke on incident dementia: A systematic review. Stroke 2010, 41, e41-e46.
71. Glass, M.; Faull, R.L.; Dragunow, M. Loss of cannabinoid receptors in the substantia nigra in huntington's disease. Neuroscience 1993, 56, 523-527.
72. Glass, M.; Dragunow, M.; Faull, R.L. The pattern of neurodegeneration in huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and gaba(a) receptor alterations in the human basal ganglia in huntington's disease. Neuroscience 2000, 97, 505-519.
73. Richfield, E.K.; Herkenham, M. Selective vulnerability in huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36, 577-584.
74. Allen, K.L.; Waldvogel, H.J.; Glass, M.; Faull, R.L. Cannabinoid (cb(1)), gaba(a) and gaba(b) receptor subunit changes in the globus pallidus in huntington's disease. J. Chem. Neuroanat. 2009, 37, 266-281.
75. Centonze, D.; Rossi, S.; Prosperetti, C.; Tscherter, A.; Bernardi, G.; Maccarrone, M.; Calabresi, P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gammaaminobutyric acid transmission in the striatum of r6/2 huntington's disease mice. Biol. Psychiatry 2005, 57, 1583-1589.
76. Denovan-Wright, E.M.; Robertson, H.A. Cannabinoid receptor messenger rna levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic huntington's disease mice. Neuroscience 2000, 98, 705-713.
77. McCaw, E.A.; Hu, H.; Gomez, G.T.; Hebb, A.L.; Kelly, M.E.; Denovan-Wright, E.M. Structure, expression and regulation of the cannabinoid receptor gene (cb1) in huntington's disease transgenic mice. Eur. J. Biochem. 2004, 271, 4909-4920.
78. Lastres-Becker, I.; Berrendero, F.; Lucas, J.J.; Martin-Aparicio, E.; Yamamoto, A.; Ramos, J.A.; Fernandez-Ruiz, J.J. Loss of mrna levels, binding and activation of gtp-binding proteins for cannabinoid cb1 receptors in the basal ganglia of a transgenic model of huntington's disease. Brain Res. 2002, 929, 236-242.
79. Glass, M.; van Dellen, A.; Blakemore, C.; Hannan, A.J.; Faull, R.L. Delayed onset of huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid cb1 receptors. Neuroscience 2004, 123, 207-212.
80. Lastres-Becker, I.; Fezza, F.; Cebeira, M.; Bisogno, T.; Ramos, J.A.; Milone, A.; Fernandez-Ruiz, J.; Di Marzo, V. Changes in endocannabinoid transmission in the basal ganglia in a rat model of huntington's disease. Neuroreport 2001, 12, 2125-2129.
81. Aiken, C.T.; Tobin, A.J.; Schweitzer, E.S. A cell-based screen for drugs to treat huntington's disease. Neurobiol. Dis. 2004, 16, 546-555.
82. Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Brouillet, E.; Fernandez-Ruiz, J. Effects of cannabinoids in the rat model of huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 2003, 14, 813-816.
83. De March, Z.; Zuccato, C.; Giampa, C.; Patassini, S.; Bari, M.; Gasperi, V.; De Ceballos, M.L.; Bernardi, G.; Maccarrone, M.; Cattaneo, E.; Fusco, F.R. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 2008, 152, 734-740.
84. Palazuelos, J.; Aguado, T.; Pazos, M.R.; Julien, B.; Carrasco, C.; Resel, E.; Sagredo, O.; Benito, C.; Romero, J.; Azcoitia, I.; Fernandez-Ruiz, J.; Guzman, M.; Galve-Roperh, I. Microglial cb2 cannabinoid receptors are neuroprotective in huntington's disease excitotoxicity. Brain 2009, 132, 3152-3164.
85. Sapp, E.; Kegel, K.B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; DiFiglia, M. Early and progressive accumulation of reactive microglia in the huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60, 161-172.
86. Pavese, N.; Andrews, T.C.; Brooks, D.J.; Ho, A.K.; Rosser, A.E.; Barker, R.A.; Robbins, T.W.; Sahakian, B.J.; Dunnett, S.B.; Piccini, P. Progressive striatal and cortical dopamine receptor dysfunction in huntington's disease: A pet study. Brain 2003, 126, 1127-1135.
87. Tai, Y.F.; Pavese, N.; Gerhard, A.; Tabrizi, S.J.; Barker, R.A.; Brooks, D.J.; Piccini, P. Microglial activation in presymptomatic huntington's disease gene carriers. Brain 2007, 130, 1759-1766.
88. de Lago, E.; Urbani, P.; Ramos, J.A.; Di Marzo, V.; Fernandez-Ruiz, J. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of huntington's disease. Brain Res. 2005, 1050, 210-216.
89. Lastres-Becker, I.; de Miguel, R.; De Petrocellis, L.; Makriyannis, A.; Di Marzo, V.; Fernandez-Ruiz, J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of huntington's disease. J. Neurochem. 2003, 84, 1097-1109.
90. Lastres-Becker, I.; Hansen, H.H.; Berrendero, F.; De Miguel, R.; Perez-Rosado, A.; Manzanares, J.; Ramos, J.A.; Fernandez-Ruiz, J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of huntington's disease. Synapse 2002, 44, 23-35.
91. Curtis, M.A.; Faull, R.L.; Glass, M. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and huntington's disease human brain. J. Chem. Neuroanat. 2006, 31, 210-215.
92. Jimenez-Del-Rio, M.; Daza-Restrepo, A.; Velez-Pardo, C. The cannabinoid cp55,940 prolongs survival and improves locomotor activity in drosophila melanogaster against paraquat: Implications in parkinson's disease. Neurosci. Res. 2008, 61, 404-411.
93. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernandez-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to parkinson's disease. Neurobiol. Dis. 2005, 19, 96-107.
94. Garcia-Arencibia, M.; Gonzalez, S.; de Lago, E.; Ramos, J.A.; Mechoulam, R.; Fernandez-Ruiz, J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007, 1134, 162-170.
95. Price, D.A.; Martinez, A.A.; Seillier, A.; Koek, W.; Acosta, Y.; Fernandez, E.; Strong, R.; Lutz, B.; Marsicano, G.; Roberts, J.L.; Giuffrida, A. Win55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson's disease. Eur. J. Neurosci. 2009, 29, 2177-2186.
96. Maneuf, Y.P.; Crossman, A.R.; Brotchie, J.M. The cannabinoid receptor agonist win 55, 212-2 reduces d2, but not d1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of parkinson's disease. Exp. Neurol. 1997, 148, 265-270.
97. Di Marzo, V.; Hill, M.P.; Bisogno, T.; Crossman, A.R.; Brotchie, J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of parkinson's disease. FASEB J. 2000, 14, 1432-1438.
98. Silverdale, M.A.; McGuire, S.; McInnes, A.; Crossman, A.R.; Brotchie, J.M. Striatal cannabinoid cb1 receptor mrna expression is decreased in the reserpine-treated rat model of parkinson's disease. Exp. Neurol. 2001, 169, 400-406.
99. Gubellini, P.; Picconi, B.; Bari, M.; Battista, N.; Calabresi, P.; Centonze, D.; Bernardi, G.; Finazzi-Agro, A.; Maccarrone, M. Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J. Neurosci. 2002, 22, 6900-6907.
100. Gerdeman, G.; Lovinger, D.M. Cb1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 2001, 85, 468-471.
101. Kelsey, J.E.; Harris, O.; Cassin, J. The cb(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of parkinson's disease. Behav. Brain Res. 2009, 203, 304-307.
102. Cao, X.; Liang, L.; Hadcock, J.R.; Iredale, P.A.; Griffith, D.A.; Menniti, F.S.; Factor, S.; Greenamyre, J.T.; Papa, S.M. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 323, 318-326.
103. Fernandez-Espejo, E.; Caraballo, I.; de Fonseca, F.R.; El Banoua, F.; Ferrer, B.; Flores, J.A.; Galan-Rodriguez, B. Cannabinoid cb1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 2005, 18, 591-601.
104. Meschler, J.P.; Howlett, A.C.; Madras, B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (mptp)-treated non-human primates. Psychopharmacology (Berl.) 2001, 156, 79-85.
105. van Vliet, S.A.; Vanwersch, R.A.; Jongsma, M.J.; Olivier, B.; Philippens, I.H. Therapeutic effects of delta9-thc and modafinil in a marmoset parkinson model. Eur. Neuropsychopharmacol. 2008, 18, 383-389.
106. Fox, S.H.; Henry, B.; Hill, M.; Crossman, A.; Brotchie, J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the mptp-lesioned nonhuman primate model of parkinson's disease. Mov. Disord. 2002, 17, 1180-1187.
107. Gilgun-Sherki, Y.; Melamed, E.; Mechoulam, R.; Offen, D. The cb1 cannabinoid receptor agonist, hu-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol. Toxicol. 2003, 93, 66-70.
108. Morgese, M.G.; Cassano, T.; Gaetani, S.; Macheda, T.; Laconca, L.; Dipasquale, P.; Ferraro, L.; Antonelli, T.; Cuomo, V.; Giuffrida, A. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist win55,212-2. Neurochem. Int. 2009, 54, 56-64.
109. Kirshner, H.S. Vascular dementia: A review of recent evidence for prevention and treatment. Curr. Neurol. Neurosci. Rep. 2009, 9, 437-442.
110. Krishnan, S.; Cairns, R.; Howard, R. Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev. 2009, CD007204.
111. Volicer, L.; Stelly, M.; Morris, J.; McLaughlin, J.; Volicer, B.J. Effects of dronabinol on anorexia and disturbed behavior in patients with alzheimer's disease. Int. J. Geriatr. Psychiatry 1997, 12, 913-919.
112. Walther, S.; Mahlberg, R.; Eichmann, U.; Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl.) 2006, 185, 524-528.
113. Cummings, J.L.; Mega, M.; Gray, K.; Rosenberg-Thompson, S.; Carusi, D.A.; Gornbein, J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994, 44, 2308-2314.
114. Passmore, M.J. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int. J. Geriatr. Psychiatry 2008, 23, 116-117.
115. Aso, E.; Renoir, T.; Mengod, G.; Ledent, C.; Hamon, M.; Maldonado, R.; Lanfumey, L.; Valverde, O. Lack of cb1 receptor activity impairs serotonergic negative feedback. J. Neurochem. 2009, 109, 935-944.
116. Bambico, F.R.; Katz, N.; Debonnel, G.; Gobbi, G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 2007, 27, 11700-11711.
117. Bellocchio, L.; Lafenetre, P.; Cannich, A.; Cota, D.; Puente, N.; Grandes, P.; Chaouloff, F.; Piazza, P.V.; Marsicano, G. Bimodal control of stimulated food intake by the endocannabinoid system. Nat. Neurosci. 2010, 13, 281-283.
118. Murillo-Rodriguez, E. The role of the cb1 receptor in the regulation of sleep. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1420-1427.
119. Murillo-Rodriguez, E.; Blanco-Centurion, C.; Sanchez, C.; Piomelli, D.; Shiromani, P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: An in vivo microdialysis study. Sleep 2003, 26, 943-947.
120. Staekenborg, S.S.; Su, T.; van Straaten, E.C.; Lane, R.; Scheltens, P.; Barkhof, F.; van der Flier, W.M. Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J. Neurol. Neurosurg. Psychiatry 2009.
121. Mangieri, R.A.; Piomelli, D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol. Res. 2007, 56, 360-366.
122. Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in huntington's disease. Mov. Disord. 2009, 24, 2254-2259.
123. Consroe, P.; Laguna, J.; Allender, J.; Snider, S.; Stern, L.; Sandyk, R.; Kennedy, K.; Schram, K. Controlled clinical trial of cannabidiol in huntington's disease. Pharmacol. Biochem. Behav. 1991, 40, 701-708.
124. Curtis, A.; Rickards, H. Nabilone could treat chorea and irritability in huntington's disease. J. Neuropsychiatry. Clin. Neurosci. 2006, 18, 553-554.
125. Muller-Vahl, K.R.; Schneider, U.; Emrich, H.M. Nabilone increases choreatic movements in huntington's disease. Mov. Disord. 1999, 14, 1038-1040.
126. Venderova, K.; Ruzicka, E.; Vorisek, V.; Visnovsky, P. Survey on cannabis use in parkinson's disease: Subjective improvement of motor symptoms. Mov. Disord. 2004, 19, 1102-1106.
127. Consroe, P.; Sandyk, R.; Snider, S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 1986, 30, 277-282.
128. Sieradzan, K.A.; Fox, S.H.; Hill, M.; Dick, J.P.; Crossman, A.R.; Brotchie, J.M. Cannabinoids reduce levodopa-induced dyskinesia in parkinson's disease: A pilot study. Neurology 2001, 57, 2108-2111.
129. Carroll, C.B.; Bain, P.G.; Teare, L.; Liu, X.; Joint, C.; Wroath, C.; Parkin, S.G.; Fox, P.; Wright, D.; Hobart, J.; Zajicek, J.P. Cannabis for dyskinesia in parkinson disease: A randomized doubleblind crossover study. Neurology 2004, 63, 1245-1250.
130. Mesnage, V.; Houeto, J.L.; Bonnet, A.M.; Clavier, I.; Arnulf, I.; Cattelin, F.; Le Fur, G.; Damier, P.; Welter, M.L.; Agid, Y. Neurokinin b, neurotensin, and cannabinoid receptor antagonists and parkinson disease. Clin. Neuropharmacol. 2004, 27, 108-110.
131. Zuardi, A.W.; Crippa, J.A.; Hallak, J.E.; Pinto, J.P.; Chagas, M.H.; Rodrigues, G.G.; Dursun, S.M.; Tumas, V. Cannabidiol for the treatment of psychosis in parkinson's disease. J. Psychopharmacol. 2009, 23, 979-983.